The Quantellect read.As of Nov 19, 2026, 11 active firms cover Bicara Therapeutics Inc. Common Stock: 8 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $20.00 to $42.00 (about 2.1x), a sign of real disagreement on valuation. The average target of $32.64 sits 247% above the current $9.40. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-1.01 next quarter toward $-3.89 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 active firms
Buy
Strong Buy00%
Buy873%
Neutral327%
Sell00%
Strong Sell00%
Based on 11 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$32.64
+247.2% upside
Average target across 11 active firms as of Nov 19, 2026 vs $9.40 current
Highest Target$42.00
Average Target$32.64
Lowest Target$20.00
Detailed analyst forecasts for BCAX
Showing 1–11 of 11 named analysts shown · 11 active firms in the rating projection
As of Nov 19, 2026, 8 of 11 active firms rate BCAX a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BCAX EPS & revenue forecast
EPS · NEXT QUARTER
$-1.01
Range $-1.19 – $-0.61 · 6 analysts · +9% YoY
Next period, 6 analysts expect Bicara Therapeutics Inc. Common Stock to earn $-1.01 a share (range $-1.19 – $-0.61), versus $-0.93 a year earlier. Full-year consensus is $-3.63, growing to $-3.89 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 6 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Bicara Therapeutics Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BCAX.
#1
David Nierengarten
Wedbush · Rank #24
Buy
$33.00+251.1% to target
Overall win rate
48%
+ Follow
#2
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$42.00+346.8% to target
Overall win rate
42%
+ Follow
#3
TA
Tazeen Ahmad
B of A Securities · Rank #411
Buy
$34.00+261.7% to target
Overall win rate
46%
+ Follow
#4
SW
Stephen Willey
Stifel · Rank #474
Buy
$45.00+378.7% to target
Overall win rate
29%
+ Follow
#5
Reni J. Benjamin
JMP Securities · Rank #489
Buy
$31.00+229.8% to target
Overall win rate
29%
+ Follow
BCAX stock forecast FAQ
What is BCAX's average 12-month price target?+
The 11 active firms with a live target average $32.64 for Bicara Therapeutics Inc. Common Stock over the next 12 months, ranging from a $42.00 high to a $20.00 low, as of Nov 19, 2026.
Is BCAX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 11 active firms as of Nov 19, 2026, 8 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BCAX?+
The Street-high target is $42.00 (Guggenheim), and the Street-low is $20.00 (Goldman Sachs). The average of all 11 active-firm targets is $32.64.
How many active Wall Street firms cover BCAX?+
11 active firms have a recognized rating on Bicara Therapeutics Inc. Common Stock as of Nov 19, 2026, and 11 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BCAX?+
Among analysts who currently cover BCAX, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #24). Their current call is Buy with a $33.00 target.
What is Bicara Therapeutics Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-1.01 per share (range $-1.19 – $-0.61) across 6 analysts. Full-year EPS is projected at $-3.63, rising to $-3.89 the following year.
How much revenue is Bicara Therapeutics Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading BCAX lately?+
As of Nov 19, 2026, 8 of 11 active firms rate BCAX a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BCAX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.